Cut Through the Fat


By: W. Langbein

Researchers have long understood that thiazolidinediones (TZDs) improve the action of insulin while increasing total fat mass as well. After studying 39 upper-body obese, insulin-resistant, but non-diabetic men and postmenopausal women, researchers concluded that patients on pioglitazone (Actos) improved their insulin resistance level regardless of the rise in intra-abdominal fat that accompanied the therapy.

Half the patients in the study were randomly assigned to receive 30 mg daily of Actos, while the other half participated in a diet and exercise program that yielded an approximate 12-kg weight loss over 20 weeks.

In spite of the increase in total body fat, particularly in the lower body, the patients on Actos experienced an improvement in insulin sensitivity.

Diabetes Care, November 2003



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.